Trial Profile
LIPEG: A Phase IV, postmarketingstudy of the safety and efficacy of Lipegfigrastim (Lonquex ) as febrileneutropenia (FN) prophylaxis in patients undergoing chemoimmunotherapy (CIT) for NonHodgkinLymphoma(NHL).
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2018
Price :
$35
*
At a glance
- Drugs Lipegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Acronyms LIPEG
- 18 Jan 2018 New trial record